Formulary Watch

Latest News


All News

Wendy Barnes and Mark Campbell of RxBenefits discuss the company’s survey, which finds employers are curious about solutions to manage both specialty drug spend and the potential volatility that comes with employees who may be diagnosed with cancer and other high-dollar conditions.

The withdrawal is related to the quality of the data collection and monitoring of the pivotal clinical trials by the clinical research organization.